(PRESS RELEASE) LOS ALTOS, CA —
SightGlass Vision today announced the release of its
first white paper regarding the company’s Diffusion Optics Technology
™ (DOT 0.2) spectacle lenses. The lenses use thousands of light scattering elements called dots, designed to mimic more natural contrast on the retina—a unique mechanism of action to slow myopia progression in children.
The in-depth paper explains the relationship between artificially high contrast signals at the retina and myopia progression. This groundbreaking research led to the development of DOT to manage such contrast, now clinically proven via the pivotal CYPRESS study to slow myopia progression in children from age six. Its efficacy is particularly of note for the youngest patients, who would typically experience the fastest progression.
The white paper can be read online or downloaded as a PDF
here
“Harnessing the power of contrast management is a revolutionary approach to controlling myopia. Our DOT spectacle lenses are now paving a new path to reducing myopia progression from an early age. This white paper goes deeper into the science to explain the mechanisms of action, helping eye care professionals better understand the innovation,” said SightGlass Vision Vice President of Clinical, Medical & Professional Affairs Marcella McParland.
“As a more recent entrant into the myopia management field, our Diffusion Optics Technology paper will help disseminate the substantial science behind contrast management and its application. DOT spectacle lenses present a compelling alternative to existing solutions for slowing myopia’s progression in children,” added Andrew Sedgwick, SightGlass Vision’s CEO.
Over the last two years, SightGlass Vision’s patent-protected technology with clinically proven efficacy1,2,3,4 made its commercial debut in several markets, including China, the Netherlands, and Israel, as well as through preliminary market trials in other countries. The company operates as a joint venture of CooperCompanies and EssilorLuxottica.
